Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12565754 | 0.84 | MAPT (0.61) | MAPTHPGDRAB9AL3MBTL1GAA | |
| SCHEMBL210295 | 0.79 | CA1 (0.58) | LMNASMN1; SMN2KMT2ATSHRALDH1A1 | |
| SCHEMBL151953 | 0.78 | CA1 (0.67) | MAPTRAB9ASTSSMN1; SMN2KMT2A | |
| SCHEMBL3301210 | 0.78 | HPGD (1.00) | MAPTHPGDRAB9AL3MBTL1GAA | |
| SCHEMBL203697 | 0.78 | HPGD (1.00) | MAPTHPGDRAB9AL3MBTL1GAA | |
| SCHEMBL540837 | 0.77 | PARP10 (0.64) | KMT2AALDH1A1 | |
| SCHEMBL50646 | 0.77 | MAPT (0.68) | MAPTHPGDRAB9AL3MBTL1GAA | |
| SCHEMBL3291543 | 0.77 | SMN1; SMN2 (0.50) | MAPTHPGDRAB9AL3MBTL1GAA | |
| SCHEMBL177478 | 0.77 | HPGD (0.68) | MAPTHPGDRAB9AMAOBSMN1; SMN2 | |
| SCHEMBL289656 | 0.77 | KMT2A (0.57) | RAB9AL3MBTL1MAOBSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| CN-120040450-A | Crystalline forms of a phosphoinositide 3 kinase (PI 3K) inhibitor | 因赛特公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-114555594-B | Substituted azacycles as TRMP modulators | 奇华顿股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-115210233-B | 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2025-02-14 | — | — | CN | disclosed |
| EP-4233864-B1 | COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-12 | — | — | EP | disclosed |
| CN-113677683-B | Crystalline forms of a phosphoinositide 3 kinase (PI 3K) inhibitor | 因赛特公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240400559-A1 | SOLID STATE EMITTERS BASED ON PYRIDINIUM SCAFFOLDS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-05 | — | — | US | disclosed |
| WO-2003006151-A1 | MICROENCAPSULATED CATALYST, METHODS OF PREPARATION AND METHODS OF USE THEREOF | AVECIA LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003005971-A2 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002733-A2 | COMPOSITIONS FOR ENHANCED CATALYZED REPORTER DEPOSITION | PERKINELMER LIFE SCIENCES, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002072031-A2 | SUBSTITUTED TETRACYCLINE COMPOUNDS AS SYNERGISTIC ANTIFUNGAL AGENTS | PARATEK PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055495-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | MAPT 2222/4885HPGD 2763/4885RAB9A 458/4885 |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | MAPT 4638/4885HPGD 1024/4885RAB9A 4602/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | MAPT 34/4885HPGD 135/4885RAB9A 952/4885 |
| US-20240400559-A1 | SOLID STATE EMITTERS BASED ON PYRIDINIUM SCAFFOLDS | CYB5R3, NQO1, SQOR | MAPT 2160/4885HPGD 593/4885RAB9A 4185/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | MAPT 2934/4885HPGD 2082/4885RAB9A 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.